• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Combination of apremilast and narrowband ultraviolet B light in the treatment of generalized vitiligo in skin phototypes IV to VI: A randomized split-body pilot study.

作者信息

Kim Hee J, Singer Giselle K, Del Duca Ester, Abittan Brian J, Chima Margot A, Kimmel Grace, Bares Jennifer, Gagliotti Matthew, Genece Jordan, Chu Justin, Wilding Gregory, Pavel Ana B, Guttman-Yassky Emma, Lebwohl Mark G

机构信息

Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York.

Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York.

出版信息

J Am Acad Dermatol. 2021 Dec;85(6):1657-1660. doi: 10.1016/j.jaad.2020.12.073. Epub 2021 Jan 10.

DOI:10.1016/j.jaad.2020.12.073
PMID:33440217
Abstract
摘要

相似文献

1
Combination of apremilast and narrowband ultraviolet B light in the treatment of generalized vitiligo in skin phototypes IV to VI: A randomized split-body pilot study.阿普斯特与窄谱中波紫外线联合治疗皮肤光型IV至VI的泛发性白癜风：一项随机半体对照初步研究。
J Am Acad Dermatol. 2021 Dec;85(6):1657-1660. doi: 10.1016/j.jaad.2020.12.073. Epub 2021 Jan 10.
2
Apremilast and narrowband ultraviolet B combination therapy suppresses Th17 axis and promotes melanogenesis in vitiligo skin: a randomized, split-body, pilot study in skin types IV-VI.阿普米司特与窄谱中波紫外线联合治疗抑制白癜风皮损中 Th17 轴并促进黑素生成：皮肤类型 IV-VI 患者的随机、分体、初步研究。
Arch Dermatol Res. 2023 Mar;315(2):215-221. doi: 10.1007/s00403-022-02343-1. Epub 2022 Mar 13.
3
Apremilast in Combination with Narrowband UVB in the Treatment of Vitiligo: A 52-Week Monocentric Prospective Randomized Placebo-Controlled Study.阿普米司特联合窄谱中波紫外线治疗白癜风：一项 52 周的单中心前瞻性随机安慰剂对照研究。
J Invest Dermatol. 2020 Aug;140(8):1533-1537.e2. doi: 10.1016/j.jid.2019.11.031. Epub 2020 Jan 29.
4
Vitiligo: Targeted Therapies Add Color to Disease Pathophysiology.白癜风：靶向治疗为疾病病理生理学增添色彩。
J Invest Dermatol. 2020 Aug;140(8):1498-1500. doi: 10.1016/j.jid.2020.01.033.
5
Topical tacrolimus may enhance repigmentation with targeted narrowband ultraviolet B to treat vitiligo: a randomized, controlled study.外用他克莫司联合靶向窄谱中波紫外线可增强白癜风复色：一项随机对照研究
Clin Exp Dermatol. 2009 Dec;34(8):e1029-30. doi: 10.1111/j.1365-2230.2009.03712.x.
6
Tetrahydrocurcuminoid cream plus targeted narrowband UVB phototherapy for vitiligo: a preliminary randomized controlled study.四氢姜黄素乳膏联合靶向窄谱中波紫外线光疗治疗白癜风：一项初步随机对照研究。
Photomed Laser Surg. 2010 Oct;28(5):679-84. doi: 10.1089/pho.2009.2637.
7
A randomized, placebo-controlled, double-blind trial comparing narrowband UV-B Plus 0.1% tacrolimus ointment with narrowband UV-B plus placebo in the treatment of generalized vitiligo.一项随机、安慰剂对照、双盲试验，比较窄谱中波紫外线联合0.1%他克莫司软膏与窄谱中波紫外线联合安慰剂治疗泛发性白癜风的疗效。
Arch Dermatol. 2006 Jul;142(7):927-9. doi: 10.1001/archderm.142.7.927.
8
Evaluation of low-dose tofacitinib combining narrowband UVB therapy for treating vitiligo patients who had failed previous therapy: A pilot study.低剂量托法替布联合窄谱中波紫外线疗法治疗既往治疗失败的白癜风患者的疗效评估：一项前瞻性研究。
Photodermatol Photoimmunol Photomed. 2021 Jul;37(4):345-347. doi: 10.1111/phpp.12661. Epub 2021 Feb 4.
9
Impact of Ultraviolet Light on Vitiligo.紫外线对白癜风的影响。
Adv Exp Med Biol. 2017;996:55-60. doi: 10.1007/978-3-319-56017-5_5.
10
The effect of platelet-rich plasma on the outcome of short-term narrowband-ultraviolet B phototherapy in the treatment of vitiligo: a pilot study.富血小板血浆对白癜风短期窄谱中波紫外线光疗疗效的影响：一项初步研究。
J Cosmet Dermatol. 2016 Jun;15(2):108-16. doi: 10.1111/jocd.12194. Epub 2015 Dec 23.

引用本文的文献

1
Emerging Therapeutic Innovations for Vitiligo Treatment.白癜风治疗的新兴治疗创新
Curr Issues Mol Biol. 2025 Mar 14;47(3):191. doi: 10.3390/cimb47030191.
2
Vitiligo: From Pathogenesis to Treatment.白癜风：从发病机制到治疗
J Clin Med. 2024 Sep 3;13(17):5225. doi: 10.3390/jcm13175225.
3
Up-and-Coming Drugs for the Treatment of Vitiligo.治疗白癜风的新兴药物
Ann Dermatol. 2024 Aug;36(4):197-208. doi: 10.5021/ad.24.038.
4
A systematic review of case series and clinical trials investigating systemic oral or injectable therapies for the treatment of vitiligo.系统回顾了一系列病例和临床试验，调查了全身性口服或注射治疗白癜风的方法。
Skin Res Technol. 2024 Mar;30(3):e13642. doi: 10.1111/srt.13642.
5
Vitiligo: Pathogenesis and New and Emerging Treatments.白癜风：发病机制与新型及新兴治疗方法。
Int J Mol Sci. 2023 Dec 9;24(24):17306. doi: 10.3390/ijms242417306.
6
Apremilast Add-On Benefits Over Conventional Drugs (ABCD) in Unstable Non-segmental Vitiligo: A 12-Week Single-Center Randomized Controlled Trial.阿普米拉斯在不稳定非节段性白癜风中作为附加治疗优于传统药物（ABCD）：一项为期12周的单中心随机对照试验。
Cureus. 2023 Apr 5;15(4):e37180. doi: 10.7759/cureus.37180. eCollection 2023 Apr.
7
Apremilast and narrowband ultraviolet B combination therapy suppresses Th17 axis and promotes melanogenesis in vitiligo skin: a randomized, split-body, pilot study in skin types IV-VI.阿普米司特与窄谱中波紫外线联合治疗抑制白癜风皮损中 Th17 轴并促进黑素生成：皮肤类型 IV-VI 患者的随机、分体、初步研究。
Arch Dermatol Res. 2023 Mar;315(2):215-221. doi: 10.1007/s00403-022-02343-1. Epub 2022 Mar 13.